Analysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX) and Biogen (BIIB)
Positive Financial Performance and Potential of Lead Assets Boost Onconova Therapeutics' Buy Rating: An Analysis by Joseph Pantginis
Promising Developments in Onconova Therapeutics' Drug Narazaciclib Bolster Buy Rating: An Analysis
Promising Clinical Results and Progress in Trials Lead to Buy Rating for Onconova Therapeutics
HC Wainwright & Co. Reiterates Buy on Onconova Therapeutics, Maintains $11 Price Target
Onconova Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Onconova Therapeutics, Maintains $11 Price Target
Onconova Therapeutics Analyst Ratings
H.C. Wainwright Sticks to Their Buy Rating for Onconova Therapeutics (ONTX)
Noble Financial Keeps Their Buy Rating on Onconova Therapeutics (ONTX)
Onconova Therapeutics (ONTX) Receives a Buy From H.C. Wainwright
HC Wainwright & Co. Reiterates Buy on Onconova Therapeutics, Maintains $11 Price Target
Onconova Therapeutics (ONTX) Gets a Buy From H.C. Wainwright
Onconova Therapeutics (ONTX) Gets a Buy From Noble Financial
Analysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX), Cara Therapeutics (CARA) and Minerva Neurosciences (NERV)
Onconova Therapeutics (ONTX) Gets a Buy From H.C. Wainwright
HC Wainwright & Co. Upgrades Onconova Therapeutics to Buy, Announces $11 Price Target
Noble Financial Sticks to Their Buy Rating for Onconova Therapeutics (ONTX)
Onconova Therapeutics (ONTX) Gets a Hold From H.C. Wainwright
H.C. Wainwright Sticks to Its Hold Rating for Onconova Therapeutics (ONTX)